| dc.contributor.author | Avalos, Ana M. | |
| dc.contributor.author | Bilate, Angelina M. | |
| dc.contributor.author | Witte, Martin D. | |
| dc.contributor.author | Tai, Albert K. | |
| dc.contributor.author | He, Jiang | |
| dc.contributor.author | Frushicheva, Maria P. | |
| dc.contributor.author | Thill, Peter Daniel | |
| dc.contributor.author | Meyer-Wentrup, Friederike | |
| dc.contributor.author | Theile, Christopher S. | |
| dc.contributor.author | Chakraborty, Arup K. | |
| dc.contributor.author | Zhuang, Xiaowei | |
| dc.contributor.author | Ploegh, Hidde | |
| dc.date.accessioned | 2014-09-25T17:10:49Z | |
| dc.date.available | 2014-09-25T17:10:49Z | |
| dc.date.issued | 2014-02 | |
| dc.date.submitted | 2013-07 | |
| dc.identifier.issn | 0022-1007 | |
| dc.identifier.issn | 1540-9538 | |
| dc.identifier.uri | http://hdl.handle.net/1721.1/90353 | |
| dc.description.abstract | Valency requirements for B cell activation upon antigen encounter are poorly understood. OB1 transnuclear B cells express an IgG1 B cell receptor (BCR) specific for ovalbumin (OVA), the epitope of which can be mimicked using short synthetic peptides to allow antigen-specific engagement of the BCR. By altering length and valency of epitope-bearing synthetic peptides, we examined the properties of ligands required for optimal OB1 B cell activation. Monovalent engagement of the BCR with an epitope-bearing 17-mer synthetic peptide readily activated OB1 B cells. Dimers of the minimal peptide epitope oriented in an N to N configuration were more stimulatory than their C to C counterparts. Although shorter length correlated with less activation, a monomeric 8-mer peptide epitope behaved as a weak agonist that blocked responses to cell-bound peptide antigen, a blockade which could not be reversed by CD40 ligation. The 8-mer not only delivered a suboptimal signal, which blocked subsequent responses to OVA, anti-IgG, and anti-kappa, but also competed for binding with OVA. Our results show that fine-tuning of BCR-ligand recognition can lead to B cell nonresponsiveness, activation, or inhibition. | en_US |
| dc.description.sponsorship | National Institutes of Health (U.S.) (grant R01 AI087879) | en_US |
| dc.description.sponsorship | National Institutes of Health (U.S.) (grant R01 GM100518) | en_US |
| dc.description.sponsorship | National Institutes of Health (U.S.) (grant P01 AI091580) | en_US |
| dc.description.sponsorship | Netherlands Organization for Scientific Research | en_US |
| dc.language.iso | en_US | |
| dc.publisher | Rockefeller University Press | en_US |
| dc.relation.isversionof | http://dx.doi.org/10.1084/jem.20131603 | en_US |
| dc.rights | Creative Commons Attribution-Noncommercial-Share Alike | en_US |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-sa/3.0/ | en_US |
| dc.source | Rockefeller University Press | en_US |
| dc.title | Monovalent engagement of the BCR activates ovalbumin-specific transnuclear B cells | en_US |
| dc.type | Article | en_US |
| dc.identifier.citation | Avalos, A. M., A. M. Bilate, M. D. Witte, A. K. Tai, J. He, M. P. Frushicheva, P. D. Thill, et al. “Monovalent Engagement of the BCR Activates Ovalbumin-Specific Transnuclear B Cells.” Journal of Experimental Medicine 211, no. 2 (February 3, 2014): 365–379. | en_US |
| dc.contributor.department | Massachusetts Institute of Technology. Institute for Medical Engineering & Science | en_US |
| dc.contributor.department | Massachusetts Institute of Technology. Department of Biological Engineering | en_US |
| dc.contributor.department | Massachusetts Institute of Technology. Department of Chemical Engineering | en_US |
| dc.contributor.department | Massachusetts Institute of Technology. Department of Chemistry | en_US |
| dc.contributor.department | Massachusetts Institute of Technology. Department of Physics | en_US |
| dc.contributor.department | Ragon Institute of MGH, MIT and Harvard | en_US |
| dc.contributor.department | Whitehead Institute for Biomedical Research | en_US |
| dc.contributor.mitauthor | Frushicheva, Maria P. | en_US |
| dc.contributor.mitauthor | Thill, Peter Daniel | en_US |
| dc.contributor.mitauthor | Chakraborty, Arup K. | en_US |
| dc.contributor.mitauthor | Ploegh, Hidde | en_US |
| dc.relation.journal | Journal of Experimental Medicine | en_US |
| dc.eprint.version | Final published version | en_US |
| dc.type.uri | http://purl.org/eprint/type/JournalArticle | en_US |
| eprint.status | http://purl.org/eprint/status/PeerReviewed | en_US |
| dspace.orderedauthors | Avalos, Ana M.; Bilate, Angelina M.; Witte, Martin D.; Tai, Albert K.; He, Jiang; Frushicheva, Maria P.; Thill, Peter D.; Meyer-Wentrup, Friederike; Theile, Christopher S.; Chakraborty, Arup K.; Zhuang, Xiaowei; Ploegh, Hidde L. | en_US |
| dc.identifier.orcid | https://orcid.org/0000-0001-6259-8800 | |
| dc.identifier.orcid | https://orcid.org/0000-0002-7487-8858 | |
| dc.identifier.orcid | https://orcid.org/0000-0003-1268-9602 | |
| dc.identifier.orcid | https://orcid.org/0000-0002-1090-6071 | |
| mit.license | PUBLISHER_CC | en_US |
| mit.metadata.status | Complete | |